Marinus Pharma (MRNS) Reports Q4 Loss of $0.45
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Jefferies Cuts Price Target on Marinus Pharma (MRNS) to $13 Following 4Q
March 8, 2016 8:34 AM ESTJefferies maintained a Buy rating on Marinus Pharmaceuticals (NASDAQ: MRNS), and cut the price target to $13.00 (from $14.00), following the company's 4Q. Total operating expenses for Q4 were $7.5M consisting of $6.1M of R&D and $1.4M G&A expense. MRNS is set to announce... More
